A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Moderately to Severely Active Ulcerative Colitis
- Interventions
- Drug: Placebo
- Registration Number
- NCT06589986
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 400
- Confirmed diagnosis of UC
- Moderately to severely active UC assessed by mMS
- Bodyweight >= 40 kilogram (kg)
- Up to date with colorectal cancer (CRC) screening performed according to local standards
- Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced UC therapy
- Males and females of childbearing potential must meet protocol criteria for contraception requirements
- Currently known complications of UC (e.g. fulminant colitis, toxic megacolon)
- Current diagnosis of Crohn's disease (CD) or indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis
- Presence of an ostomy or ileoanal pouch
- Current diagnosis or suspicion of primary sclerosing cholangitis
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study
- Past or current evidence of definite low-grade or high-grade colonic dysplasia or adenomas or neoplasia not completely removed
- History of malignancy within 5 years, with the exception of malignancies adequately treated with resection for non-metastatic basal cell or squamous cell cancer or in situ cervical cancer
- Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV)
- Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB
- Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description RO7790121 RO7790121 Participants will receive RO7790121 intravenously (IV) followed by RO7790121 subcutaneous (SC) injection. Placebo Placebo Participants will receive placebo IV followed by placebo SC.
- Primary Outcome Measures
Name Time Method Percentage of Participants with Clinical Remission at Week 12 At Week 12 Percentage of participants achieving Modified Mayo Score (mMS) \<=2 with stool frequency subscore (SFS) = 0 or 1 (up to 1-2 stools more than normal), rectal bleeding subscore (RBS) = 0 (no blood seen) and endoscopic subscore (ES) = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.
Percentage of Participants with Clinical Remission at Week 52 At Week 52 Percentage of participants achieving mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.
- Secondary Outcome Measures
Name Time Method Change in Partial Modified Mayo Score (pmMS) Baseline to Week 2 Change in pmMS from baseline to Week 2. pmMS is a composite score of ulcerative colitis signs and symptoms activity given by the sum of the SFS and RBS. SFS is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal). RBS is measured on a scale from 0 (no blood seen) to 3 (blood alone passed).
Percentage of Participants with Endoscopic Improvement At Week 52 Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 52.
Percentage of Participants with Endoscopic Remission At Week 52 Percentage of participants achieving endoscopic subscore of 0 (normal appearance of mucosa) at Week 52.
Percentage of Participants with Clinical Response At Week 12 Percentage of participants achieving a decrease in mMS of at least 2 points and 30% from baseline and either a decrease in RBS \>= 1 or RBS = 0 or 1 (no blood seen or stool with streaks of blood) at Week 12. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. SFS is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal). RBS is measured on a scale from 0 (no blood seen) to 3 (blood alone passed). ES is measured on a scale from 0 (normal appearance of mucosa) to 3 (severe disease).
Percentage of Participants with Histologic Improvement At Week 52 Percentage of participants achieving histologic improvement defined as Geboes \<= 3.1 at Week 52.
Percentage of Participants with Histologic Remission At Week 52 Percentage of participants achieving histologic remission defined as Geboes \<2B at Week 52.
Percentage of Participants with Histologic-Endoscopic Mucosal Improvement At Week 52 Percentage of participants achieving Geboes \<= 3.1 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).
Percentage of Participants with Histologic-Endoscopic Remission At Week 52 Percentage of participants achieving Geboes \< 2 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).
Percentage of Participants with Maintenance of Remission Week 12 and Week 52 Percentage of participants with clinical remission at both Week 12 and Week 52. Clinical remission is defined as mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease). mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.
Percentage of Participants with Corticosteroid-Free Remission At Week 52 Percentage of participants in clinical remission at Week 52 with no corticosteroid use at least 8 weeks prior to Week 52. Clinical remission is defined as mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease). mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.
Percentage of Participants with Clinical remission: Among Biomarker-Defined Subgroups of Participants At Week 52 Percentage of participants achieving mMS \<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52 in biomarker-defined subgroups. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.
Percentage of Participants with Endoscopic Improvement: Among Biomarker-Defined Subgroups of Participants At Week 52 Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 52 in biomarker-defined subgroups.
Change in Bowel Urgency Baseline through Week 52 Change in bowel urgency from baseline through Week 52. Bowel urgency is measured on a scale from 0 (None) to 4 (Severe).
Change in Abdominal Pain Baseline through Week 52 Change in abdominal pain from baseline through Week 52. Abdominal pain is measured on a scale from 0 (None) to 4 (Severe).
Change in Fatigue Baseline to Week 12 and Week 52 Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) from baseline to Week 12 and Week 52. FACIT-Fatigue is a 13-item self-reported assessment of the level and impact of fatigue. The overall FACIT-Fatigue score ranges between 0 and 52, with higher scores associated with better quality of life concerns related to fatigue.
Change in Health-Related Quality of Life Baseline to Week 12 and Week 52 Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline to Week 12 and Week 52. IBDQ is a 32-item self-reported assessment of health-related quality of life in participants with inflammatory bowel disease. The overall IBDQ score ranges from 32 to 224, with higher scores associated with better health-related quality of life.
Overall Change in UC Symptoms Baseline to Week 2, Week 12, and Week 52 Patient Global Impression of Change (PGIC) from baseline to Weeks 2, 12 and 52. PGIC measures overall change in ulcerative colitis symptoms from "Much better" to "Much worse".
Overall Severity in UC Symptoms Baseline to Week 2, Week 12, and Week 52 Patient Global Impression of Severity (PGIS) from baseline to Weeks 2, 12 and 52. PGIS measures severity of ulcerative colitis symptoms from "None" to "Very severe".
Incidence and Severity of Adverse Events (AEs) Up to 70 Weeks after Baseline Incidence and severity of AEs, including serious AEs, AEs leading to treatment discontinuation and AEs of special interest.
Trial Locations
- Locations (209)
Medwal
🇨🇱Santiago, Chile
AZ Delta (Campus Rumbeke)
🇧🇪Roeselare, Belgium
Vitaz
🇧🇪Sint Niklaas, Belgium
MHAT St. Ivan Rilski
🇧🇬Gorna Oryahovitsa, Bulgaria
MHAT Kaspela
🇧🇬Plovdiv, Bulgaria
CHRU de Lille - Hopital Claude Huriez
🇫🇷Lille, France
Vistamed & Vertigo Spó?Ka Z Ograniczon? Odpowiedzialno?Ci?
🇵🇱Wroc?aw, Poland
Melita Medical
🇵🇱Wroclaw, Poland
ETG Zamosc
🇵🇱Zamo??, Poland
Hospital de Braga
🇵🇹Braga, Portugal
Hospital da Luz Lisboa
🇵🇹Lisboa, Portugal
Hospital Sao Teotonio
🇵🇹Viseu, Portugal
Hopital Robert Debre
🇫🇷Reims, France
Gokeikai Ofuna Chuo Hospital
🇯🇵Kanagawa, Japan
Kinshukai Infusion Clinic
🇯🇵Osaka, Japan
Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan
🇺🇸Dothan, Alabama, United States
Arizona Digestive Health, P.C (ADH)
🇺🇸Sun City, Arizona, United States
University of California Irvine
🇺🇸Orange, California, United States
UCSF/Medical Center at Mount Zion
🇺🇸San Francisco, California, United States
Amicis Research Center
🇺🇸Santa Clarita, California, United States
Peak Gastroenterology Associates
🇺🇸Colorado Springs, Colorado, United States
Peak Gastroenterology Surgery Center
🇺🇸Lone Tree, Colorado, United States
Access Research Institute
🇺🇸Brooksville, Florida, United States
Gastro Florida
🇺🇸Clearwater, Florida, United States
J&A Clinical Research
🇺🇸Doral, Florida, United States
Clinical Research of Osceola, LLC
🇺🇸Kissimmee, Florida, United States
Auzmer Research
🇺🇸Lakeland, Florida, United States
Miami Beach Clinical Research Center
🇺🇸Miami Beach, Florida, United States
Homestead Associates in Research, Inc.
🇺🇸Miami, Florida, United States
Allied Biomedical Research Institute, Inc
🇺🇸Miami, Florida, United States
Eminat Research Group
🇺🇸Miramar, Florida, United States
Nodal Medical Center, LLC
🇺🇸Tampa, Florida, United States
Theia Clinical Research Centers, LLC
🇺🇸Tampa, Florida, United States
Florida Medical Clinic
🇺🇸Zephyrhills, Florida, United States
Sjaellands Universitetshospital, Køge
🇩🇰Køge, Denmark
Gastroenterology Associates of Central Georgia
🇺🇸Macon, Georgia, United States
Grand Teton Research Group, PLLC
🇺🇸Idaho Falls, Idaho, United States
Next Innovative Clinical Research
🇺🇸Chicago, Illinois, United States
The University of Chicago
🇺🇸Chicago, Illinois, United States
Indiana University Health University Hospital
🇺🇸Indianapolis, Indiana, United States
Gastroenterology Health Partners, PLLC
🇺🇸Louisville, Kentucky, United States
Tri-State Gastroenterology Associates
🇺🇸Crestview Hills, Kentucky, United States
Louisiana Research Center - GastroIntestinal Associates
🇺🇸Shreveport, Louisiana, United States
Mercy Medical Center
🇺🇸Baltimore, Maryland, United States
Brigham & Womens Hosp
🇺🇸Boston, Massachusetts, United States
Boston University
🇺🇸Boston, Massachusetts, United States
Michigan Center of Medical Research
🇺🇸Farmington Hills, Michigan, United States
Allied Gastrointestinal Associates, PA
🇺🇸Flowood, Mississippi, United States
Gastroenterology Associates and Endoscopy Center of North Mississippi
🇺🇸Oxford, Mississippi, United States
BVL Clinical Research
🇺🇸Liberty, Missouri, United States
Intercity Gastroenterology
🇺🇸Fresh Meadows, New York, United States
Pioneer Clinical Research NY
🇺🇸New York, New York, United States
New York-Presbyterian Hospital-Columbia University Medical Center
🇺🇸New York, New York, United States
Digestive Health Partners, PA
🇺🇸Asheville, North Carolina, United States
Peters Medical Research (PMR), LLC
🇺🇸High Point, North Carolina, United States
Monroe Biomedical Research
🇺🇸Monroe, North Carolina, United States
Digestive Disease Consultants
🇺🇸Brunswick, Ohio, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Ohio Gastroenterology Group
🇺🇸Columbus, Ohio, United States
CHU Amiens - Hopital Sud
🇫🇷Amiens, France
Great Lakes Gastroenterology Research, LLC
🇺🇸Mentor, Ohio, United States
Gastro Intestinal Research Institute of Northern Ohio
🇺🇸Westlake, Ohio, United States
Central Sooner Research
🇺🇸Norman, Oklahoma, United States
University Gastroenterology
🇺🇸Providence, Rhode Island, United States
Gastro One
🇺🇸Cordova, Tennessee, United States
Gastrointestinal Associates of Northeast Tennessee
🇺🇸Johnson City, Tennessee, United States
Quality Medical Research
🇺🇸Nashville, Tennessee, United States
Texas Clinical Research Institute, LLC
🇺🇸Arlington, Texas, United States
Texas Digestive Disease Consultants - Cedar Park
🇺🇸Cedar Park, Texas, United States
Proactive El Paso,LLC
🇺🇸El Paso, Texas, United States
GI Alliance
🇺🇸Garland, Texas, United States
TDDC dba GI Alliance Research
🇺🇸Mansfield, Texas, United States
Digestive System Healthcare - Biopharma Informatic, LLC
🇺🇸Pasadena, Texas, United States
Carta - Clinical Associates In Research Therapeutics Of America;LLC
🇺🇸San Antonio, Texas, United States
Southern Star Research Institute, LLC.
🇺🇸San Antonio, Texas, United States
GI Alliance - Southlake
🇺🇸Southlake, Texas, United States
Tyler Research Institute, LLC
🇺🇸Tyler, Texas, United States
University of Texas Health Center at Tyler
🇺🇸Tyler, Texas, United States
Tidewater Gastroenterology Pllc T/A Gastro. Assoc. of Tidewater
🇺🇸Chesapeake, Virginia, United States
Gastroenterology Consultants and Endoscopy Center of Southwest Virginia
🇺🇸Roanoke, Virginia, United States
Marshall Health
🇺🇸Huntington, West Virginia, United States
CIPREC Centro de Investigacion y Prevencion Cardiovascular
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Expertia S.A- Mautalen Salud e Investigación
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Royal Prince Alfred Hospital
🇦🇺Sydney, New South Wales, Australia
Mater Misericordiae Limited
🇦🇺South Brisbane, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Lyell McEwin Hospital
🇦🇺Adelaide, South Australia, Australia
Northern Hospital
🇦🇺Epping, Victoria, Australia
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Medizinische Universität Innsbruck
🇦🇹Innsbruck, Austria
Medizinische Universität Wien
🇦🇹Wien, Austria
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
CHC MontLégia
🇧🇪Liege, Belgium
CHU Sart-Tilman
🇧🇪Liège, Belgium
South Edmonton Gastroenterology
🇨🇦Edmonton, Alberta, Canada
Queen Elizabeth II Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
TDDA Specialty Research
🇨🇦Woodbridge, Ontario, Canada
Hospital Guillermo Grant Benavente
🇨🇱Concepcion, Chile
Clinica Universidad de Los Andes
🇨🇱Santiago, Chile
Binzhou Medical university hospital
🇨🇳Binzhou, China
the First Hospital of Jilin University
🇨🇳Changchun, China
Sichuan Provincial People's Hospital
🇨🇳Chengdu, China
The First Affiliated Hospital Of Fujian Medical University
🇨🇳Fuzhou City, China
The First Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou City, China
The sixth affiliated hospital of Sun Yat-Sen University
🇨🇳Guangzhou City, China
Anhui Provincial Hospital
🇨🇳Hefei, China
The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, China
Huizhou First Hospital
🇨🇳Huizhou, China
Jinhua municipal central hospital
🇨🇳Jinhua, China
The 1st Affiliated Hospital of Nanchang Unversity
🇨🇳Nanchang City, China
Nanjing 1st Hospital
🇨🇳Nanjing, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, China
Hebei Medical University - The Second Hospital
🇨🇳Shijiazhuang City, China
The First Hospital of Shanxi Medical University
🇨🇳Taiyuan, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan City, China
Ren Min Hospital Affiliated Wu Han University
🇨🇳Wuhan, China
Wuxi People's Hospital
🇨🇳Wuxi, China
The Second Affiliated Hospital of Xi'an Jiao Tong University
🇨🇳Xi'an City, China
The Second Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, China
Zhuzhou Central Hospital
🇨🇳Zhuzhou, China
Borzan Polyclinic
🇭🇷Osijek, Croatia
SurGal Clinic s.r.o.
🇨🇿Brno, Czechia
Gastroenterologie s.r.o.
🇨🇿Hradec Kralove, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Herlev Hospital
🇩🇰Herlev, Denmark
CHU Dijon Bourgogne Hôpital François Mitterand
🇫🇷Dijon, France
CH Dptal Les Oudairies
🇫🇷La Roche Sur Yon, France
Hopital Nord
🇫🇷Marseille, France
Institut des MICI, Clinique Ambroise Paré
🇫🇷Neuilly sur Seine, France
CHU Nice - Hopital de l'Archet 2
🇫🇷Nice, France
CHU Bordeaux - Hôpital Haut-Lévêque
🇫🇷Pessac, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre-Benite, France
CHU de Rennes - Hopital de Pontchaillo
🇫🇷Rennes, France
CHU Saint Etienne - Hôpital Nord
🇫🇷Saint Etienne, France
Hôpital de Rangueil
🇫🇷Toulouse, France
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
🇩🇪Berlin, Germany
Klinik Johann Wolfgang von Goethe Uni
🇩🇪Frankfurt, Germany
Universitaetsklinikum Halle (Saale)
🇩🇪Halle, Germany
Universitaetsklinikum Jena
🇩🇪Jena, Germany
Klinikum Mannheim GmbH Universitätsklinikum
🇩🇪Mannheim, Germany
Universitätsklinikum Ulm
🇩🇪Ulm, Germany
Clinexpert Kft.
🇭🇺Budapest, Hungary
Obudai Egeszsegugyi Centrum Kft.
🇭🇺Budapest, Hungary
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Pannonia Maganorvosi Centrum
🇭🇺Budapest, Hungary
Bekes Varmegyei Kozponti Korhaz, dr Rethy Pal Tagkorhaz
🇭🇺Békéscsaba, Hungary
Heves County Markhot Ferenc Teaching Hospital
🇭🇺Eger, Hungary
Gyöngyösi Bugát Pál Kórház
🇭🇺Gyöngyös, Hungary
Clinfan Szolgaltato Kft.
🇭🇺Szekszard, Hungary
Jávorszky Ödön Kórház
🇭🇺Vác, Hungary
Ospedale Madonna delle Grazie
🇮🇹Matera, Basilicata, Italy
Universita'degli Studi di Napoli Federico II
🇮🇹Napoli, Campania, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Asst Santi Paolo E Carlo
🇮🇹Milano, Lombardia, Italy
ASST Rhodense - Ospedale di Rho
🇮🇹Rho, Lombardia, Italy
IRCCS Ospedale Casa Sollievo della Soffenza
🇮🇹San Giovanni Rotondo, Lombardia, Italy
Ospedale Mauriziano Umberto I
🇮🇹Torino, Piemonte, Italy
Azienda Ospedaliera di Padova
🇮🇹Padova, Veneto, Italy
Tsujinaka Hospital Kashiwanoha
🇯🇵Chiba, Japan
Fukuoka University - Chikushi Hospital
🇯🇵Chikushino-shi, Japan
Japanese Red Cross Takayama Hospital
🇯🇵Gifu, Japan
Sai Gastroenterology/Proctology Clinic
🇯🇵Osaka, Japan
Saga-ken Medical Centre Koseikan
🇯🇵Saga, Japan
Tokitokai Tokito Clinic
🇯🇵Saitama, Japan
Matsuda Hospital
🇯🇵Shizuoka, Japan
Kitasato University Kitasato Institute Hospital
🇯🇵Tokyo, Japan
JCHO Tokyo Yamate Medical Center
🇯🇵Tokyo, Japan
Universitair Medisch Centrum Utrecht
🇳🇱Utrecht, Netherlands
SPZOZ w ??cznej
🇵🇱??czna, Poland
Clinical Trials UMED Sp. z o. o.
🇵🇱?ód?, Poland
Uniwersytecki Szpital Kliniczny W Bia?Ymstoku
🇵🇱Bia?ystok, Poland
Centrum Medyczne "Medis"
🇵🇱Bydgoszcz, Poland
Centrum Medyczne Lukamed Joanna Luka-Wendrowska
🇵🇱Chojnice, Poland
Endo-Med Sp. z o.o.
🇵🇱Karczew, Poland
Allmedica Badania Kliniczne Sp z o.o. Sp K.
🇵🇱Nowy Targ, Poland
Wojewodzki Specjalistyczny Szpital w Olsztynie
🇵🇱Olsztyn, Poland
NZOZ Eskulap Pabianice
🇵🇱Pabianice, Poland
Trialmed CRS
🇵🇱Piotrków Trybunalski, Poland
SOLUMED Centrum Medyczne
🇵🇱Pozna?, Poland
Centrum Medyczne "MEDYK"
🇵🇱Rzeszów, Poland
Kiepury Clinic
🇵🇱Sosnowiec, Poland
Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj
🇵🇱Toru?, Poland
WIP Warsaw IBD Point Profesor Kierkus
🇵🇱Warsaw, Poland
Centralny Szpital Kliniczny MSW w Warszawie
🇵🇱Warszawa, Poland
Przychodnia EuroMediCare
🇵🇱Wroc?aw, Poland
Centro Hospitalar do Algarve - Hospital de Portimao
🇵🇹Portimao, Portugal
Hospital de Sao Joao
🇵🇹Porto, Portugal
Centro Hospitalar de Entre Douro e Vouga - H. São Sebastião
🇵🇹Santa Maria Da Feira, Portugal
Colentina Clinical Hospital
🇷🇴Bucharest, Romania
Cantacuzino Clinical Hospital
🇷🇴Bucharest, Romania
University Hospital Center Dr Dragisa Misovic - Dedinje
🇷🇸Belgrade, Serbia
University Hospital Medical Center Zvezdara
🇷🇸Belgrade, Serbia
University Hospital Medical Center Bezanijska Kosa
🇷🇸Beograd, Serbia
Clinical Center of Vojvodina
🇷🇸Novi Sad, Serbia
Cliniq s.r.o.
🇸🇰Bratislava, Slovakia
ABAWI spol. s r.o.
🇸🇰Bratislava, Slovakia
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Cantabria, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Division of Gastroenterology, Depart of Medicine, Fac of Med., Chulalongkorn University
🇹🇭Bangkok, Thailand
Division of Gastroenterology, Depart of Internal Med, Siriraj H, Mahidol Uni
🇹🇭Bangkok, Thailand
Liver Research Unit, Srinagarind Hospital
🇹🇭Khon Kaen, Thailand
Thammasat University Hospital
🇹🇭Pathumthani, Thailand
Division of Gastroenterology, Depart of Medicine, Fac. of Med, Songklanagarind University
🇹🇭Songkhla, Thailand
Surin hospital
🇹🇭Surin, Thailand
Royal Liverpool University Hospital
🇬🇧Liverpool, United Kingdom